Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr) is an important early event in signal transduction, leading to cell replication for major human carcinomas. CP-358,774 is a potent and selective inhibitor of the EGFr tyrosine kinase and produces selective inhibition of EGF-mediated tumor cell mitogenesis. To assess the pharmacodynamic aspects of EGFr inhibition, we devised an ex vivo enzyme-linked immunosorbent assay for quantification of EGFr-specific tyrosine phosphorylation in human tumor tissue specimens obtained from xenografts growing s.c. in athymic mice. When coupled with pharmacokinetic analyses, this measurement can be used to describe the extent and duration of kinase inhibition in vivo. CP-358,774 is an effective, orally active inhibitor of EGFr-specific tyrosine phosphorylation (ED(50) = 10 mg/kg, single dose). It has a significant duration of action, producing, on average, a 70% reduction in EGFr-associated phosphotyrosine over a 24-h period after a single 100 mg/kg dose. Inhibition of EGFr phosphotyrosine in an ex vivo assay format effectively estimates the potency and degree of inhibition of EGFr-dependent human LICR-LON-HN5 head and neck carcinoma tumor growth. Substantial growth inhibition of human tumor xenografts was achieved with p.o. doses of the compound (ED(50) = 10 mg/kg q.d. for 20 days). Combination chemotherapy with cisplatin produced a significant response above that of cisplatin alone with no detectable effects on body weight or lethal toxicity. Taken together, these observations suggest that CP-358,774 may be useful for the treatment of EGFr-driven human carcinomas.
Pollack
V A
VA
Department of Genomics, Targets and Cancer Research, Pfizer Central Research, Groton, Connecticut 06340, USA. vincent_a_pollack@groton.pfizer.com
Savage
D M
DM
Baker
D A
DA
Tsaparikos
K E
KE
Sloan
D E
DE
Moyer
J D
JD
Barbacci
E G
EG
Pustilnik
L R
LR
Smolarek
T A
TA
Davis
J A
JA
Vaidya
M P
MP
Arnold
L D
LD
Doty
J L
JL
Iwata
K K
KK
Morin
M J
MJ
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism; D019338:Polypharmacy; D011799:Quinazolines / Q000097:blood / Q000494:pharmacology*; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000502:physiology; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000378:metabolism*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011799:Quinazolines; D019000:Phosphotyrosine; D014443:Tyrosine; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D002945:Cisplatin